Stemride International Ltd. - Offers lines of normal human embryonic stem cells, and genetically abnormal variants to scientists and researchers. with sub-licensing to commercial and scientific institutions from London, UK.
BeFutur Biotechnologies - Company conducts research using autologous human cells in a serum free medium to treat incurable diseases. The results propose possible new treatments for regeneration of diseased tissues. Based in Geneva, Switzerland.
TheraVitae Co.,Ltd. - Developing therapy by the transplantation of the patient's own cell-line after isolation and processing in vitro, to replace, repair or enhance the function of damaged tissues. Clinical trials based in Bangkok, Thailand and Kiryat Weizmann, Israel.
Pluristem Life Systems Inc. - Specializing initially in hematopoietic stem cells and developing expansion from umbilical cord blood using its proprietary bioreactor and 3-D technology platform. Includes investor data and overview of company in Haifa, Israel.
ReNeuron Ltd. - Developing somatic transplantation technology for diabetes, neuronal degeneration and therapy for brain damage including stroke, Parkinson's disease, Alzheimer's and Huntington's disease. Overview of company in Guildford, England.
Stemcell Technologies - Specialist contract research organaization, offering kits for selection and enrichment from embryonic, epithelial hematopoietic or neural origin, and cloning of either hybridomas or non-adherent stably transfected cells. International laboratories headquartered from the USA.
TriStem Corp. - Research and development of retrodifferentiation technology, used to create stem cells from mature adult cells. Includes technological and corporate overview, with FAQ and contacts in London, UK.
XYClone Zona Laser Drill - Offers stem cell researchers a method of opening the zona for insertion or withdrawal of genetic material. From Hamilton Thorne Biosciences Inc., Beverly, Massachusetts
Geron Corporation - Incorporated in the state of Delaware in 1990, Geron has been in business since 1992. The Company’s headquarters and main facilities are located in Menlo Park, California. The Company also has a subsidiary in Edinburgh, Scotland. Geron is a biopharmaceutical company developing and commercializing three groups of products: i) therapeutic products for oncology that target telomerase; ii) pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and iii) cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases. (Nasdaq: GERN)
Abcam: Stem Cells - Antibodies, markers, reagents and recent reviews of their applications, links to conferences. Online catalog and purchase available from Cambridge, England and Massachusetts.
Vet-Stem, Inc. - Offers isolation and concentration from a sample of fat for treatment of injuries to tendons, ligaments, and fractures in performance horses. Includes explanation, case studies, news, description of services for horse owners and veterinarians, with contacts in Poway, California.
Intercytex Ltd. - Biotech company in the field of cell therapies including skin and hair regeneration products. Currently in clinical phase 3 trials in the USA, Canada and UK, headquartered in Cambridge, England.
Odontis Ltd. - Formed in 2002 to develop new in vivo tissue engineering technology for damaged or missing teeth, including growth of patient-matched dental implants. Contacts and introduction to research at Guy’s Hospital, London, UK.
Chris Mason - Consultant to the global stem cell, tissue engineering and regenerative medicine industry.
Cells Limited - Offers ISO 17025 compliant storage of stem cells derived from the umbilical cord blood or bone marrow, and associated testing in Harrow, England.
ViaCell, Inc. - Developing therapies for the treatment of bone defects and myocardial regeneration, utilizing somatic stem cells isolated from cord blood. Based in Cambridge, Massachusetts.
CellResearch Corp. Pte. Ltd. - Inventors of ethical umbilical cord mesenchymal and epithelial progenitor cell lines targeted at regenerative medicine. Also offering primary skin cell culture systems, both normal and diseased, and customised research in Singapore.
Axordia - Axordia is one of the UK’s leading human embryonic stem cell (hESC) companies. It has a unique portfolio of patent protected technologies and proprietary materials - GMP derived hESC lines; the capacity to produce key cell line derivatives, including a patent protected endovascular line with powerful potential; RNA interference (RNAi); Wnt and Notch signalling; a suite of hESC biomarkers.
Capsant Neurotechnologies - The company's primary drug evaluation focus is in the field of chronic and acute neurodegenerative diseases. Capsant has pioneered and developed a number of in-vitro, 3-dimentional tissue-based (organotypic) models that closely mimic many of the characteristics of major CNS disorders such as stroke, Alzheimer's Disease, MS and epilepsy.
CellTran - CellTran has developed advanced polymer surface technology and has optimised methods for the culture of autologous and allogeneic cells.
CXR Biosciences - Drug discovery and development tools including the deployment of stem cell technologies
EpiStem - An independent contract research company providing pre-clinical research services to the biotechnology and pharmaceutical industries.
NovaThera - REgenerative medicine company with interests in both tissue engineering scaffolds and human embryonic stem cells. Particularly interested in lung tissue.
Plasticell - Plasticell is a privately held biotechnology company using novel stem cell culture and drug discovery platforms to produce regenerative small molecule drugs.
Stem Cell Sciences - Stem Cell Sciences' principal objective is to be the first company to deliver clinical benefit from an embryonic stem cell-derived cell therapy. This requires multiple technologies and a globally integrated initiative.
VetCell Bioscience - VetCell BioScience investigates, develops and commercialises new technologies for veterinary use. The company focuses on cellular therapeutics for the regeneration and functional restoration of damaged and diseased tissue.
InbioBank - Non profit, adult stem cell bank that produces stem and primary cells at cGMP quality standards for cellular therapy and basic research.
Embryotech - Medical Center of Cell and Tissue Therapy Embryotech. The Centre deals cell therapy, cryobiology and cell biology. cryopreservation of stem cells and specialized cells clinic providing a range of laboratory diagnostics for the purpose of conducting an integrated estimation of patient"s condition as well as individual selection of cell transplants.
Advanced Cell Technology, Inc. - Advanced Cell Technology, Inc. is a biotechnology company applying human embryonic stem cell technology in the emerging field of regenerative medicine. The Company operates facilities in Alameda, California and Worcester, Massachusetts. They own or license over 300 patents and patent applications related to the field of stem cell therapy, nuclear transfer which allows the production of stem cells genetically matched to the patient, and a reduced complexity library of stem cells for acute clinical applications. Collectively, they believe that their intellectual property represents one of the strongest portfolios in the field. The Company is focused on being the first to commercialize the most profitable applications of regenerative medicine.
Advanced BioHealing, Inc. - Advanced BioHealing, Inc. (ABH) is a specialty biotechnology company focused on the development and marketing of cell based and tissue engineered products for wound care. They are a privately held, New York based company, with two FDA approved products: Dermagraft and TransCyte. Their development pipeline also includes a next-generation bioengineered wound therapy for which an Investigational Device Exemption application (IDE) has been submitted to the FDA. In 2006, Advanced BioHealing purchased the manufacturing and marketing rights to Dermagraft (human fibroblast-derived dermal substitute) and Transcyte (a human fibroblast-derived temporary skin substitute) from Smith & Nephew. ABH is on target to return Dermagraft to the market in 2007 following manufacturing improvements at the company's La Jolla, California facility.
California Institute of Regenerative Medicine (CIRM) - The California Institute for Regenerative Medicine (CIRM) is a state agency that was established through the passage of Proposition 71, the "California Stem Cell Research and Cures Initiative". The statewide ballot measure, which provided $3 billion in funding for stem cell research at Californian universities and research institutions, was approved by California voters on November 2, 2004, and called for the establishment of a new state agency to make grants and provide loans for stem cell research, research facilities and other vital research opportunities. The CIRM will function using bond proceeds to fund basic and applied biomedical research focused on developing diagnostics and therapies and on other vital research opportunities that will lead to life-saving medical treatments. All proposals are peer-reviewed to support the most promising scientific research. Research grants are made only to California-based research institutions. CIRM is overseen by an Independent Citizens Oversight Committee (ICOC). The 29 ICOC members are public officials, appointed on the basis of their experience earned in California's leading public universities, non-profit academic and research institutions, patient advocacy groups and the biotechnology industry.
Cellerant Therapeutics, Inc. - Cellerant Therapeutics, Inc. is a clinical stage biotechnology company with a portfolio of products based on the regulation of the human haematopoietic (blood-forming) system. The company focuses on curative therapies for seriously ill patients. Currently Cellerant has three major products under development, including developing pure haematopoietic stem cells (CLT-001) for therapeutic applications in cancer, genetic blood disorders and autoimmune diseases. The Company is also developing a novel, cell-based medicine (Myeloid Progenitors / CLT-008) as a treatment for chemotherapy and radiation induced neutropenia (abnormally low levels of a particular white blood cell) as well as for Acute Radiation Syndrome. The company is also applying their considerable expertise in hematopoietic biology to identify novel drug targets and therapeutic antibodies aimed at cancer stem cells.
Cerco Medical LLC - Cerco Medical LLC’s mission is to develop cellular-based therapies to treat common diseases through the application of their proprietary encapsulation technology. The company's implantable thin-sheet devices make cell therapy potentially possible without the requirement for toxic immune suppression therapy. The company’s sole current focus is an implantable bio-artificial pancreas device to treat diabetes called the “Islet Sheet”. The Company is carrying out preclinical studies of the alginate-based "Islet Sheet" technology in animal models of diabetes and anticipates clinical trials within the next two years.
Cognate BioServices, Inc. - Cognate BioServices, Inc. is a value-added provider of development and cGMP manufacturing services to companies developing a variety of cell therapy technologies. Cognate is a fully integrated company with highly experienced technical staff and management team, along with fully validated cGMP manufacturing facilities on both Coasts and state of the art research and development laboratories. Cognate also has the ability to rapidly advance technology from early research stages through pre-clinical and process development, cGMP manufacturing and scale-up, regulatory submission and into the clinic. Cognate fills a unique role in supporting development of cell-based therapeutics and has substantial experience in the successful development of cell-based therapeutic products that have been introduced into human clinical trials through IND applications to the FDA. Members of Cognate’s staff have played a material role in the development of 16 successful stem cell and cellular product IND applications with the FDA.
Cytori Therapeutics, Inc. - Cytori Therapeutics, Inc. is discovering and developing proprietary, cell-based therapeutics utilising adult stem cells derived from adipose (fat) tissue. The company's investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders and new approaches for aesthetic and reconstructive surgery. To facilitate the processing and surgical delivery of adipose stem cells, Cytori is developing its proprietary Celution™ System to process and concentrate a patient's own stem cells in approximately a one-hour period of time. This system will dramatically improve the speed in which personalised (autologous), cell-based therapies can be delivered to patients.
Primogenix, Inc. - Providesg investigators with access to mouse embryonic stem cells derived from standard research strains as well as transgenic and knockout models. The company's products and services include stem cell isolation and validation, differentiation, electroporation and mouse chimera production.
Progenitor Cell Therapy LLC - A client-based cell therapy services company that supports the development and commercialization of cellular therapies. PCT provides cGMP-compliant cell manufacturing and consulting services. Services include support related to process and product development, validation, due diligence evaluations, tissue collection, processing, and storage, product manufacturing, distribution and transportation. Facilities in Hackensack, NJ and Mountain View, CA.
Proteus Venture Partners - Proteus Venture Partners is a team of experienced investment and operations professionals who came together to establish a regenerative medicine fund - "The Proteus Fund". The team has aligned itself with key players in academia, industry and government. The Proteus Advisory Board represents the top leaders of stem cell and regenerative medicine research, thus assimilating the thought leaders of this sector. The Proteus Fund is a $150 Million fund focusing on cell therapies, tissue engineering, tools and devices and aesthetic medicines. They plan to invest in companies across a broad range of development, from early stage companies seeking their first institutional round of financing, to small-cap public companies seeking PIPE (private investment in public equity) financing. Their investment focus is not limited by geography, for example, they expect to make a number of investments in the UK, Canada, Israel and other centres of excellence outside of the United States.
StemCells, Inc. - Researches, develops, and markets cell-based therapies, with details of clinical trials and information for investors.
Synthasome, Inc. - Synthasome, Inc. is a biotechnology company developing products for regenerative medicine, primarily for musculoskeletal applications, using tissue-engineering technologies. The company has a product pipeline, NIH-funded projects and patents have been submitted. The first products are those that can be brought to market relatively quickly and with modest investment. The revenues from these early products will then be used to drive the future R&D program. Thus the overall objective of Synthasome is to develop products that meet previously unmet clinical needs in reparative medicine using tissue engineering technology within a financially profitable and independent organisation.
Theregen, Inc. - Theregen, Inc. (formerly Iken Tissue Therapeutics) is a regenerative medicine company that develops cell-based therapies for patients with cardiovascular and vascular disease. Theregen has worldwide exclusive rights to research, manufacture, develop and commercialise its lead product Anginera, for cardiovascular and peripheral vascular disease applications. Currently, the company is conducting a Phase I human clinical safety trial for Anginera, a cell-based epicardial therapy. In pre-clinical studies, Anginera has been shown in animal models to have the potential to induce remodeling and angiogenesis (new blood vessel formation) in the ischemic heart, leading to functional changes that may benefit patients with heart failure.
VistaGen Therapeutics, Inc. - VistaGen Therapeutics, Inc. is a biopharmaceutical company developing breakthrough drugs for disorders of the Central Nervous System (CNS) and diabetes. Their lead drug candidate AV-101 targets two large CNS markets epilepsy and neuropathic pain. Their key R&D partnership applies their clinically predictive in vitro embryonic stem cell technologies to discover and develop a new generation of drug candidates for diabetes and other metabolic syndrome diseases. They are developing an internal pipeline of products to provide late-stage product opportunities for large pharmaceutical companies by advancing new generation drug candidates through Phase 2 clinical trials and pursuing partnerships to complete Phase 3 development and commercialisation.
Stem Cell Translation Ltd. - Consultancy company providing services to the stem cell + regenerative medicine industry.
"Tissue Engineering" journal - Tissue Engineering is the authoritative peer-reviewed journal that jointly applies the principles of engineering and life sciences. The Journal provides a fundamental understanding of structure-function relationships in normal and pathologic tissues with the ultimate goal of developing biological substitutes. The Journal brings together scientific and medical experts in the fields of biomedical engineering, biomaterials science, molecular and cell biology, genetic engineering, and surgery to present and discuss advances in this emerging field. The Official Journal of TERMIS —Tissue Engineering and Regenerative Medicine International Society.
Toucan Capital Corp. - Leading U.S. investor in stem cells and regenerative medicine companies.
NeuroGeneration - Biotherapeutic company developing autologous differentiated neural stem cell therapies for neurological disorders in Los Angeles, California.
|